infection, whether vaccinated with two doses or with three, the risk of hospitalization of severe illness in israeli data set is the same. so the trillion dollars question becomes how long does this protection in the 60-plus age group last? if it's months or years, it makes sense do it. if there is no effect in younger people who actually have a higher rate of adverse effects that are important and we give everyone a choice without data, we will be shooting ourselves in the foot if there is a subgroup of people, like younger males who, for example, had much more side effects after two doses. it could be a major problem if the third dose doesn't help them, but hirts them. the israeli data suggests it might be a good idea for the 60 plus group. >> if it works in the 60 plus group, is there a reason why it wouldn't work in the 20 plus group? and by the way, israel is now